Current and emerging strategies in osteoporosis management

Current Pharmaceutical Design

Volumn 23, Issue 41, 2017, Pages 6279-6287

  Ivanova, Stefka ^a   Vasileva, Liliya ^b,c  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^c MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

Author keywords

Osteoporosis; Pharmacology; Physical activity; Phytotherapy; Prevention; Treatment

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; COLONY STIMULATING FACTOR 1; DENOSUMAB; ESTROGEN; GESTAGEN; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 6; ODANACATIB; OSTEOCALCIN; OSTEOPRETEGRIN TRANSCRIPTION FACTOR 2; PARATHYROID HORMONE[1-34]; PHYTOESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN; STRONTIUM RANELATE; TAMOXIFEN; TESTOSTERONE CIPIONATE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VITAMIN D; BONE DENSITY CONSERVATION AGENT; CALCIUM;

APOPTOSIS; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CALCIUM INTAKE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DRUG EFFICACY; EXERCISE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; TREATMENT DURATION; VITAMIN INTAKE; ANIMAL; DRUG EFFECT;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; EXERCISE; HUMANS; OSTEOPOROSIS; RISK FACTORS; VITAMIN D;

EID: 85027359913     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170714122714     Document Type: Review

References (95)

1. Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367(9527): 2010-8.
2. Dempster D W. Osteoporosis and the burden of osteoporosisrelated fractures. Am J Manag Care 2011; 17(Suppl 6): S164-9.
3. Becker DJ, Kilgore ML, Morrisey MA. The societal burden of osteoporosis. Curr Rheumatol Rep 2010; 12(3): 186-91.
4. Mukudai Y, Kondo S, Koyama T, et al. Potential anti-osteoporotic effects of herbal extracts on osteoclasts, osteoblasts and chondrocytes in vitro. BMC Complement Altern Med 2014; 14(1): 29.
5. Lewiecki EM, Bilezikian JP, Binkley N, et al. Update on osteoporosis from the 2014 Santa Fe Bone symposium. Endocr Res 2015; 40(2): 106-19.
6. Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: Screening and treatment strategies. Ther Adv Musculoskelet Dis 2014; 6(5): 185-202.
7. Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: Mechanisms and clinical implications. Am J Med 2010; 123(10): 877-84.
8. Maricic M. Update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 2011; 37(3): 415-431, vi.
9. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 2012; 41(3): 595-611.
10. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: Now and the future. Lancet 2011; 377(9773): 1276-87.
11. Baccaro LF, Conde DM, Costa-Paiva L, Pinto-Neto AM. The epidemiology and management of postmenopausal osteoporosis: A viewpoint from Brazil. Clin Interv Aging 2015; 10: 583-91.
12. van der Klift M, de Laet CE, McCloskey EV, et al. Risk factors for incident vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 2004; 19(7): 1172-80.
13. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012; 23(9): 2239-56.
14. Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep 2008; 10(2): 92-6.
15. Waugh EJ, Lam MA, Hawker GA, et al. Risk factors for low bone mass in healthy 40-60 year old women: A systematic review of the literature. Osteoporos Int 2009; 20(1): 1-21.
16. Gerend MA, Erchull MJ, Aiken LS, Maner JK. Reasons and risk: Factors underlying women’s perceptions of susceptibility to osteoporosis. Maturitas 2006; 55(3): 227-37.
17. Thomas JM. Risk factors of osteoporosis. Rev Med Brux 2008; 29(4): 285-8.
18. Cohen AJ, Roe FJ. Review of risk factors for osteoporosis with particular reference to a possible aetiological role of dietary salt. Food Chem Toxicol 2000; 38(2-3): 237-53.
19. Hallstrom H, Wolk A, Glynn A, Michaelsson K. Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. Osteoporos Int 2006; 17(7): 1055-64.
20. Hallstrom H, Byberg L, Glynn A, Lemming EW, Wolk A, Michaelsson K. Long-term coffee consumption in relation to fracture risk and bone mineral density in women. Am J Epidemiol 2013; 178(6): 898-909.
21. Azuma K, Adachi Y, Hayashi H, Kubo K-Y. Chronic psychological stress as a risk factor of osteoporosis. J UOEH 2015; 37(4): 245-53.
22. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: A meta-analysis. Osteoporos Int 2005; 16(2): 155-62.
23. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005; 16(7): 737-42.
24. Te H, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Osteoporos Int 2011; 7: CD000333.
25. Adams J, Pepping J. Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. Am J Health Syst Pharm 2005; 62(15): 1574-81.
26. Ivanova S, Vasileva L, Ivanova S, Peikova L, Obreshkova D. Osteoporosis: Therapeutic Options. Folia Med (Plovdiv) 2015; 57(3-4): 181-90.
27. Raisz LG. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 2005; 115(12): 3318-25.
28. Gallagher JC. Advances in bone biology and new treatments for bone loss. Maturitas 2008; 60(1): 65-9.
29. Pankova V, Stefka Vasileva, Liliya Petkova, “A Review of Current Treatment Options for Osteoporosis in Bulgaria. World J Pharm Pharm Sci 2015; 4(5): 1-12.
30. Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci 2006; 1092: 385-96.
31. Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism. J Clin Pathol 2008; 61(5): 577-87.
32. Rosen CJ, Postmenopausal osteoporosis. N Engl J Med 2005; 353: 595-603.
33. World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level 2004.
34. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24(1): 23-57.
35. Katzung BG, Masters SB, Trevor AJ. Basic and clinical. Pharmacology 2012.
36. Halldorsson BV, Bjornsson AH, Gudmundsson HT, Birgisson EO, Ludviksson BR, Gudbjornsson B. A clinical decision support system for the diagnosis, fracture risks and treatment of osteoporosis. Comput Math Methods Med 2015; 2015: 189769.
37. Ferrucci L, Baroni M, Ranchelli A, et al. Interaction between bone and muscle in older persons with mobility limitations. Curr Pharm Des 2014; 20(19): 3178-97.
38. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 2014; 25(10): 2359-81.
39. Schmitt NM, Schmitt J, Doren M. The role of physical activity in the prevention of osteoporosis in postmenopausal women-An update. Maturitas 2009; 63(1): 34-8.
40. Dionyssiotis Y, Skarantavos G, Papagelopoulos P. Modern rehabilitation in osteoporosis, falls, and fractures. Clin Med Insights Arthritis Musculoskelet Disord 2014; 7: 33-40.
41. Avenell A, Gillespie WJ, Gillespie LD, O’Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cohrane Database Systematic 2009; 2: CD000227.
42. Prentice A. Diet, nutrition and the prevention of osteoporosis. Public Health Nutr 2004; 7(1A): 227-43.
43. Levis S, Lagari VS. The role of diet in osteoporosis prevention and management. Curr Osteoporos Rep 2012; 10(4): 296-302.
44. Leung P-C, Siu W-S. Herbal treatment for osteoporosis: a current review. J Tradit Complement Med 2013; 3(2): 82-7.
45. Sun Y, Lee SM, Wong YM, et al. Dosing effects of an antiosteoporosis herbal formula-a preclinical investigation using a rat model. Phytother Res 2008; 22(2): 267-73.
46. Spilmont M, Leotoing L, Davicco MJ, et al. Pomegranate peel extract prevents bone loss in a preclinical model of osteoporosis and stimulates osteoblastic differentiation in vitro. Nutrients 2015; 7(11): 9265-84.
47. Spilmont M, Leotoing L, Davicco MJ, et al. Pomegranate and its derivatives can improve bone health through decreased inflammation and oxidative stress in an animal model of postmenopausal osteoporosis. Eur J Nutr 2014; 53(5): 1155-64.
48. Li L, Qu Y, Jin X, et al. Protective effect of salidroside against bone loss via hypoxia-inducible factor-1α pathway-induced angiogenesis. Sci Rep 2016; 6: 32131.
49. Zhang JK, Yang L, Meng GL, et al. Protection by salidroside against bone loss via inhibition of oxidative stress and boneresorbing mediators. PLoS One 2013; 8(2): e57251.
50. Sunyecz JA. The use of calcium and vitamin D in the management of osteoporosis. Ther Clin Risk Manag 2008; 4(4): 827-36.
51. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. Lancet 2007; 370(9588): 657-66.
52. Garriguet D. Bone health: Osteoporosis, calcium and vitamin D. Health Rep 2011; 22(3): 7-14.
53. Wilczynski C, Camacho P. Calcium use in the management of osteoporosis: Continuing questions and controversies. Curr Osteoporos Rep 2014; 12(4): 396-402.
54. Turner A G, Anderson P H, Morris H A. Vitamin D and bone health. Scand J Clin Lab Invest Suppl 2012; 243(no. Suppl 243): 65-72.
55. Bandeira F, Griz L, Dreyer P, Eufrazino C, Bandeira C, Freese E. Vitamin D deficiency: A global perspective. 2006; 50(4): 640-6.
56. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(7): 1911-30.
57. Bikle DD. Vitamin D and bone. Curr Osteoporos Rep 2012; 10(2): 151-9.
58. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007; 86(11): 1022-33.
59. Miller PD. The treatment of osteoporosis. Antiresorptive therapy. ClinLab Med 2000; 20(3): 603-22.
60. European Medicines Agency. Guideline on the Evaluation of Medicinal Products in the Treatment of Primary Osteoporosis 2006.
61. Le Goff B, Guillot P, Glemarec J, Berthelot JM, Maugars Y. A comparison between bisphosphonates and other treatments for osteoporosis. Curr Pharm Des 2010; 16(27): 3037-44.
62. Bartl R, Bartl C. Current prevention and treatment strategies for osteoporosis. Fracture-oriented, effective, low side effects and inexpensive. Internist (Berl) 2015; 56(12): 1445-57.
63. B. I.E.M., and L. W.F., “Glucocorticoid-induced osteoporosis. Clin Exp Rheumatol 2011; 29(5) (Suppl 68): S93-8.
64. Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83(9): 1032-45.
65. Papapoulos S, Makras P. Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2008; 4(9): 514-23.
66. Lopez-D’alessandro E, Mardenlli F, Paz M. Oral bisphosphonateassociated osteonecrosis of maxillary bone: A review of 18 cases. J Clin Exp Dent 2014; 6(5): e530-4.
67. Sharma A, Chatterjee S, Arbab-Zadeh A, et al. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: Evidence from a meta-analysis. Chest 2013; 144(4): 1311-22.
68. Sayed-Noor A S. Bisphosphonate-induced femoral fragility fractures: What do we know? Orthop Res Rev 2010; 2: 27-34.
69. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 2012; 66(12): 1139-46.
70. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011; 48(4): 677-92.
71. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: The freedom and stand studies. J Bone Miner Res 2010; 25(10): 2256-65.
72. Moen MD, Keam SJ. Denosumab: A review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 2011; 28(1): 63-82.
73. Khosla S. Increasing options for the treatment of osteoporosis. N Engl J Med 2009; 361(8): 818-20.
74. Lindsay R, Cosman F. The Pharmacology of Estrogens in Osteoporosis. Principles of Bone Biology 2008; Vol. 2: 1769-75.
75. Nelson ER, Wardell SE, McDonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis. Bone 2013; 53(1): 42-50.
76. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women’s Health Initiative randomized trial. JAMA 2003; 290(13): 1729-38.
77. Gambacciani M, Levancini M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Przegla̜d menopauzalny Menopause Rev 2014; 13(4): 213-20.
78. Tuck SP, Francis RM. Testosterone, bone and osteoporosis. Front Horm Res 2009; 37: 123-32.
79. Gizzo S, Saccardi C, Patrelli TS, et al. Update on raloxifene: Mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv 2013; 68(6): 467-81.
80. Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 2000; 295(2): 431-7.
81. Cummings-Vaughn LA, Gammack JK. Falls, osteoporosis, and hip fractures. Med Clin North Am 2011; 95(3): 495-506.
82. Nardone V, D’Asta F, Brandi ML. Pharmacological management of osteogenesis. Clinics (Sao Paulo) 2014; 69(6): 438-46.
83. Civitelli R. Calcitonin in Osteoporosis. Osteoporosis: Fourth Edition 2013; 1839-58.
84. Sacco SM, Horcajada M-N, Offord E. Phytonutrients for bone health during ageing. Br J Clin Pharmacol 2013; 75(3): 697-707.
85. Stransky M, Rysava L. Nutrition as prevention and treatment of osteoporosis. Physiol Res 2009; 58(Suppl 1): S7-S11.
86. Taku K, Melby MK, Nishi N, Omori T, Kurzer MS. Soy isoflavones for osteoporosis: An evidence-based approach. Maturitas 2011; 70(4): 333-8.
87. Li B, Liu H, Jia S. Puerarin enhances bone mass by promoting osteoblastogenesis and slightly lowering bone marrow adiposity in ovariectomized rats. Biol Pharm Bull 2014; 37(12): 1919-25.
88. Liu H, Li W, Jia S, Li B. Puerarin and zinc additively prevent mandibular bone loss through inhibiting osteoclastogenesis in ovariectomized rats. Histol Histopathol 2016; 32(8): 851-6.
89. Liu H, Li W, Ge X, Jia S, Li B. Coadministration of puerarin (low dose) and zinc attenuates bone loss and suppresses bone marrow adiposity in ovariectomized rats. Life Sci 2016; 166: 20-6.
90. Cranney A, Papaioannou A, Zytaruk N, et al. Parathyroid hormone for the treatment of osteoporosis: A systematic review. CMAJ 2006; 175(1): 52-9.
91. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: Final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 2009; 24(4): 726-36.
92. Agency EM. PRAC recommends suspending use of Protelos/Osseor (strontium ranelate) Recommendation by PRAC to be considered by CHMP for final opinion. 2014 April; 44: 1-2.
93. Rizzoli R. Strontium ranelate in the prevention of osteoporotic fractures. Osteoporosis: Fourth Edition 2013; 1935-47.
94. Ivana T, Ljiljana T, Nada VS, Katarina I, Dejan S. New drugs for osteoporosis therapy: A review of the clinical trials phase 2 and 3. Acta Fac Medicae Naissensis 2014; 31(1): 29-39.
95. Meier C, Lamy O, Krieg MA, et al. The role of teriparatide in sequential and combination therapy of osteoporosis. Swiss Med Wkly 2014; 144: w13952.